Identification of a major B-cell epitope of the Plasmodium falciparum glutamate-rich protein (GLURP), targeted by human antibodies mediating parasite killing

Vaccine

Volumn 19, Issue 2-3, 2000, Pages 204-212

  Theisen, Michael ^a   Soe, Soe ^b,c   Jessing, Stine G ^a   Okkels, Limei Meng ^a   Danielsen, Steffen ^a   Oeuvray, Claude ^c   Druilhe, Pierre ^c   Jepsen, Søren ^a  

^a STATENS SERUM INSTITUT   (Denmark)

^b Department of Medical Research ^*  (Myanmar)

^c INSTITUT PASTEUR   (France)

Author keywords

Antibody Dependent Cellular Inhibition; B cell epitope; Glutamate rich protein; Phase display; Plasmodium falciparum

Indexed keywords

EPITOPE; GLUTAMATE RICH PROTEIN; IMMUNOGLOBULIN ANTIBODY; PARASITE ANTIBODY; PROTOZOAL PROTEIN; UNCLASSIFIED DRUG;

ADULT; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; B LYMPHOCYTE; CLINICAL IMMUNOLOGY; CONTROLLED STUDY; EPITOPE MAPPING; HUMAN; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; PARASITE IDENTIFICATION; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL;

EID: 0034666704     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(00)00181-X     Document Type: Article

References (29)

1. Alonso P.L., Smith T., Schellenberg J.R., Masanja H., Mwankusye S., Urassa H., Bastos de Azevedo I., Chongela J., Kobero S., Menendez C., et al. Randomised trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania. Lancet. 344:1994;1175-1181.
2. Borre M.B., Dziegiel M., Hogh B., Petersen E., Rieneck K., Riley E., Meis J.F., Aikawa M., Nakamura K., Harada M. Primary structure and localization of a conserved immunogenic Plasmodium falciparum glutamate rich protein (GLURP) expressed in both the preerythrocytic and erythrocytic stages of the vertebrate life cycle. Mol. Biochem. Parasitol. 49:1991;119-131.
3. Boudin C., Chumpitazi B., Dziegiel M., Peyron F., Picot S., Hogh B., Ambroise-Thomas P. Possible role of specific immunoglobulin M antibodies to Plasmodium falciparum antigens in immunoprotection of humans living in a hyperendemic area, Burkina Faso. J. Clin. Microbiol. 31:1993;636-641.
4. Bouharoun-Tayoun H., Attanath P., Sabchareon A., Chongsuphajaisiddhi T., Druilhe P. Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes. J. Exp. Med. 172:1990;1633-1641.
5. Bouharoun-Tayoun H., Druilhe P. Antibodies in falciparum malaria what matters most, quantity or quality? Mem. Inst. Oswaldo. Cruz. 87:(Suppl 3):1992;229-234.
6. Bouharoun-Tayoun H., Oeuvray C., Lunel F., Druilhe P. Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages. J. Exp. Med. 182:1995;409-418.
7. Cohen S., McGregor A., Carrington S. Gamma globulin and aquired immunity to human malaria. Nature. 192:1961;733-737.
8. D'Alessandro U., Leach A., Drakeley C.J., Bennett S., Olaleye B.O., Fegan G.W., Jawara M., Langerock P., George M.O., Targett G.A., et al. Efficacy trial of malaria vaccine SPf66 in Gambian infants. Lancet. 346:1995;462-467.
9. Druilhe P., Khusmith S. Epidemiological correlation between level of antibodies promoting merozoite phagocytosis of Plasmodium falciparum and malaria-immune status. Infect. Immun. 55:1987;888-891.
10. Druilhe P., Perignon J.L. Mechanisms of defense against P. falciparum asexual blood stages in humans. Immunol. Lett. 41:1994;115-120.
11. Druilhe P., Sabchareon A., Bouharoun-Tayoun H., Oeuvray C., Perignon J.L. In vivo veritas: lessons from immunoglobulin-transfer experiments in malaria patients. Ann. Trop. Med. Parasitol. 91:(Supp.):1997;37-53.
12. Dziegiel M., Rowe P., Bennett S., Allen S.J., Olerup O., Gottschau A., Borre M., Riley E.M. Immunoglobulin M and G antibody responses to Plasmodium falciparum glutamate-rich protein: correlation with clinical immunity in Gambian children. Infect. Immun. 61:1993;103-108.
13. Hogh B., Petersen E., Dziegiel M., David K., Hanson A., Borre M., Holm A., Vuust J., Jepsen S. Antibodies to a recombinant glutamate-rich Plasmodium falciparum protein: evidence for protection of individuals living in a holoendemic area of Liberia. Am. J. Trop. Med. Hyg. 46:1992;307-313.
14. Jacobsson K, Frykberg L. Phage display shot-gun cloning of ligand-binding domains of prokaryotic receptors approaches 100% correct clones. Biotechniques 1996; 20: 1070-6, 1078, 1080-1.
15. Khusmith S., Druilhe P. Antibody-dependent ingestion of P. falciparum merozoites by human blood monocytes. Parasite. Immunol. 5:1983;357-368.
16. Khusmith S., Druilhe P. Cooperation between antibodies and monocytes that inhibit in vitro proliferation of Plasmodium falciparum. Infect. Immun. 41:1983;219-223.
17. Kolaskar A.S., Tongaonkar P.C. A semi-empirical method for prediction of antigenic determinants on protein antigens. FEBS Lett. 276:1990;172-174.
18. Kwiatkowski D., Marsh K. Development of a malaria vaccine. Lancet. 350:1997;1696-1701.
19. Lunel F., Druilhe P. Effector cells involved in nonspecific and antibody-dependent mechanisms directed against Plasmodium falciparum blood stages in vitro. Infect. Immun. 57:1989;2043-2049.
20. Mathiesen M.J., Christiansen M., Hansen K., Holm A., Asbrink E., Theisen M. Peptide-based OspC enzyme-linked immunosorbent assay for serodiagnosis of Lyme borreliosis. J. Clin. Microbiol. 36:1998;3474-3479.
21. McGregor I.A. The passive transfer of human malarial immunity. Am. J. Trop. Med. Hyg. 13:1964;237-239.
22. Nosten F., Luxemburger C., Kyle D.E., Ballou W.R., Wittes J., Wah E., Chongsuphajaisiddhi T., Gordon D.M., White N.J., Sadoff J.C., Heppner D.G. Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand. Shoklo SPf66 Malaria Vaccine Trial Group. Lancet. 348:1996;701-707.
23. Plessis D., Jordaan F. Phage libraries displaying random peptides derived from a target sequence. Kay B.K., Winter J., McCafferty J. Phage display of peptides and proteins, A laboratory manual. 1996;141-150 Academic Press, San Diego.
24. Sabchareon A., Burnouf T., Ouattara D., Attanath P., Bouharoun-Tayoun H., Chantavanich P., Foucault C., Chongsuphajaisiddhi T., Druilhe P. Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria. Am. J. Trop. Med. Hyg. 45:1991;297-308.
25. Shi Y.P., Udhayakumar V., Oloo A.J., Nahlen B.L., Lal A.A. Differential effect and interaction of monocytes, hyperimmune sera, and immunoglobulin G on the growth of asexual stage Plasmodium falciparum parasites. Am. J. Trop. Med. Hyg. 60:1999;135-141.
26. Stricker K, Vuust J, Jepsen S, Oeuvray C, Theisen M. Conservation and heterogeneity of the Glutamate-rich protein (GLURP) among field and laboratory isolates of Plasmodium falciparum. 2000, submitted.
27. Theisen M., Soe S., Oeuvray C., Thomas A.W., Vuust J., Danielsen S., Jepsen S., Druilhe P. The glutamate-rich protein (GLURP) of Plasmodium falciparum is a target for antibody-dependent monocyte-mediated inhibition of parasite growth in vitro. Infect. Immun. 66:1998;11-17.
28. Theisen M., Vuust J., Gottschau A., Jepsen S., Hogh B. Antigenicity and immunogenicity of recombinant glutamate-rich protein of Plasmodium falciparum expressed in Escherichia coli. Clin. Diagn. Lab. Immunol. 2:1995;30-34.
29. Valero M.V., Amador L.R., Galindo C., Figueroa J., Bello M.S., Murillo L.A., Mora A.L., Patarroyo G., Rocha C.L., Rojas M., et al. Vaccination with SPf66, a chemically synthesised vaccine, against Plasmodium falciparum malaria in Colombia. Lancet. 341:1993;705-710.